Sermorelin vs Tesamorelin: Research Comparison
A Side-By-Side Research Comparison Of Sermorelin And Tesamorelin - two GHRH analogs studied on the growth-hormone axis. This Reference Compares Mechanism, Evidence Tier, Molecular Identity, And Pharmacokinetics For Qualified Researchers. For In Vitro Laboratory Research Use Only. Not Medical Advice Or Dosing Guidance.
Side-By-Side Comparison
| Sermorelin | Tesamorelin | |
|---|---|---|
| Category | Muscle Growth & Performance | Muscle Growth & Performance |
| Compound Class | Synthetic 29-amino acid fragment of endogenous GHRH (GHRH 1-29-NH2) | Synthetic GHRH analog with trans-3-hexenoic acid modification at N-terminus; FDA-approved for HIV lipodystrophy |
| Evidence Tier | Approved Drug | Approved Drug |
| Molecular Target | GHRH receptor (GHRHR) on anterior pituitary somatotrophs; stimulates endogenous GH gene expression and release | GHRH receptor (GHRHR) on pituitary somatotrophs; GH/IGF-1 axis stimulation; preferential visceral fat metabolism |
| Molecular Weight | 3357.93 Da | 5135.9 Da |
| Amino Acid Sequence | GHRH(1-29) amide | hGHRH(1-44) with trans-3-hexenoyl |
| CAS Number | 86168-78-7 | 218949-48-5 |
| Half-Life | ~10-20 min | ~26-38 minutes |
| Studied For | Pituitary GH-reserve diagnostic, Pediatric GH deficiency (historical), Adult GH-axis / anti-aging research, GH secretagogue research | HIV-associated lipodystrophy (FDA approved), Hepatic fat / NAFLD research, Cognition research in aging/HIV, GH deficiency |
About Sermorelin
A growth-hormone-releasing hormone analog formerly approved for childhood GH deficiency; banned in sport.
Read The Full Sermorelin MonographAbout Tesamorelin
An FDA-approved growth-hormone-releasing hormone analog used to reduce visceral fat in HIV-associated lipodystrophy; banned in sport.
Read The Full Tesamorelin MonographKey Differences
- Reported half-life differs: Sermorelin at ~10-20 min versus Tesamorelin at ~26-38 minutes.
- Primary molecular target differs: Sermorelin acts on GHRH receptor (GHRHR) on anterior pituitary somatotrophs; stimulates endogenous GH gene expression and release; Tesamorelin acts on GHRH receptor (GHRHR) on pituitary somatotrophs; GH/IGF-1 axis stimulation; preferential visceral fat metabolism.
Continue Researching
This Comparison Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption, Diagnosis, Or Treatment. See The Full Research Disclaimer.